Efficacy of routine therapy combined levosimendan in the treatment of chronic progressive heart failure

AIM To observe the efficacy of routine therapy combined with levosimendan in the treatment of chronic progressive heart failure. METHODS 150 chronic progressive heart failure patients selected by General Hospital of Guangzhou Military Command of PLA and Qionghai people hospital were treated with levosimendan for 28 days with symptomatic and conventional anti-heart failure drugs. Changes in cardiac function index before and after the treatment were observed, and side effects of the drugs were documented. RESULTS After levosimendan treatment, the left ventricular end-diastolic dimension (LVEDD) in 77.3% patients significantly decreased when compared with cardiac state before administration, LVEDD decreased from (57±6) mm to (49±5) mm (P <0.01); Left atrial diameter diminished from (40±4) mm to (34±5) mm. The left ventricular ejection fraction increased from (32±5)% to (40±8)% (P<0.01), and serum NT-proBNP levels decreased from (3.3±1.6) ng/ml to (1.9±1.2) ng/ml (P<0.01). Eleven patients showed adverse reactions, the incidence of adverse reactions was 0.73%. CONCLUSION Therapy combined with levosimendan has a significant therapeutic effect on chronic progressive heart failure, which can effectively relieve ventricular remodeling and has a good safety profile.